Steve Bradley appointed as Cegedim UK Group MD

Steve Bradley appointed as Cegedim UK Group MD

Cegedim, an innovative technology and services company, is thrilled to announce the the appointment of Steve Bradley as Group Managing Director for its UK companies. Cegedim’s UK brands include Vision, BlueBay Medical, Cegedim Rx, Healthi, RESIP and THIN. Steve's appointment coincides with Max Brighton's retirement from the business. Max was Vision's Chief Executive Officer for the past seventeen years. These changes take immediate effect.

Steve is a highly experienced and proven business leader. He is passionate about energising the workplace and empowering teams to innovate. For the past twenty years, Steve has worked in life sciences, healthcare technology and informatics. In 2013 he joined Cegedim as General Manager of the Swiss, and then the UK Customer Relationship Management businesses. Three years later he was appointed Managing Director of Cegedim RX, where he has inspired a significant cultural transformation, enthusing the company as it approaches the launch of compelling new pharmacy software and information solutions during 2018.

Steve has a crystal clear mission for Cegedim UK: to lead the market with innovative healthcare technology, data and informatics solutions, underpinned by three interconnected, equally important and valued goals:

  1. To create new products and solutions that precisely match its customers' needs, improve healthcare provision and expedite improvements in care and outcomes.
  2. Distinct differentiation from its competitors through the committed delivery of outstanding customer experience, that’s passionately embedded at the heart of everything it does and says.
  3. To develop talent and promote an open, empowered, collaborative and energised culture that embraces change, nurtures innovation and makes Cegedim UK an inspirational place to work.

Tags: Cegedim RX, Blue Bay

Share This Story, Choose Your Platform!
Related Posts
May 9, 2018  |   0 Comments
April 30, 2018  |   0 Comments
April 2, 2018  |   0 Comments